Anderson LL, Ametovski A, Lin Luo J, et al. Cannabichromene, Related Phytocannabinoids, and 5-Fluoro-cannabichromene Have Anticonvulsant Properties in a Mouse Model of Dravet Syndrome. ACS Chem Neurosci 2021;12(2):330-339. View abstract.
Czégény Z, Nagy G, Babinszki B, et al. CBD, a precursor of THC in e-cigarettes. Sci Rep 2021;11(1):8951. View abstract.
De Petrocellis L, Ligresti A, Moriello AS, et al. Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. Br J Pharmacol. 2011;163(7):1479-94. View abstract.
De Petrocellis L, Orlando P, Moriello AS, et al. Cannabinoid actions at TRPV channels: effects on TRPV3 and TRPV4 and their potential relevance to gastrointestinal inflammation. Acta Physiol (Oxf). 2012;204(2):255-66. View abstract.
El-Alfy AT, Ivey K, Robinson K, et al. Antidepressant-like effect of delta9-tetrahydrocannabinol and other cannabinoids isolated from Cannabis sativa L. Pharmacol Biochem Behav 2010;95(4):434-42. View abstract.
Hatoum NS, Davis WM, Waters IW, Elsohly MA, Turner CE. Synergism of cannabichromene and CNS depressants in mice. Gen Pharmacol. 1981;12(5):351-6. View abstract.
Izzo AA, Capasso R, Aviello G, et al. Inhibitory effect of cannabichromene, a major non-psychotropic cannabinoid extracted from Cannabis sativa, on inflammation-induced hypermotility in mice. Br J Pharmacol. 2012;166(4):1444-60. View abstract.
Khodadadi H, Salles ÉL, Shin E, et al. A potential role for cannabichromene in modulating TRP channels during acute respiratory distress syndrome. J Cannabis Res 2021;3(1):45. View abstract.
Maione S, Piscitelli F, Gatta L, et al. Non-psychoactive cannabinoids modulate the descending pathway of antinociception in anaesthetized rats through several mechanisms of action. Br J Pharmacol. 2011;162(3):584-96. View abstract.
O'Neil JD, Dalton WS, Forney RB. The effect of cannabichromene on mean blood pressure, heart rate, and respiration rate responses to tetrahydrocannabinol in the anesthetized rat. Toxicol Appl Pharmacol. 1979;49(2):265-70. View abstract.
Peters EN, MacNair L, Mosesova I, et al. Pharmacokinetics of cannabichromene in a medical cannabis product also containing cannabidiol and ?(9)-tetrahydrocannabinol: a pilot study. Eur J Clin Pharmacol 2022;78(2):259-265. View abstract.
Romano B, Borrelli F, Fasolino I, et al. The cannabinoid TRPA1 agonist cannabichromene inhibits nitric oxide production in macrophages and ameliorates murine colitis. Br J Pharmacol. 2013;169(1):213-29. View abstract.
Shinjyo N, Di Marzo V. The effect of cannabichromene on adult neural stem/progenitor cells. Neurochem Int. 2013;63(5):432-7. View abstract.
Stahl V, Vasudevan K. Comparison of Efficacy of Cannabinoids versus Commercial Oral Care Products in Reducing Bacterial Content from Dental Plaque: A Preliminary Observation. Cureus 2020;12(1):e6809. View abstract.
Udoh M, Santiago M, Devenish S, McGregor IS, Connor M. Cannabichromene is a cannabinoid CB2 receptor agonist. Br J Pharmacol. 2019;176(23):4537-4547. View abstract.
Wirth PW, Watson ES, ElSohly M, Turner CE, Murphy JC. Anti-inflammatory properties of cannabichromene. Life Sci. 1980;26(23):1991-5. View abstract.
Wong H, Cairns BE. Cannabidiol, cannabinol and their combinations act as peripheral analgesics in a rat model of myofascial pain. Arch Oral Biol. 2019;104:33-39. View abstract.
Zagzoog A, Mohamed KA, Kim HJJ, et al. In vitro and in vivo pharmacological activity of minor cannabinoids isolated from Cannabis sativa. Sci Rep 2020;10(1):20405. View abstract.